Skip to content
Biodatica
Start free

SYNTR HEALTH TECHNOLOGIES, LLC

Irvine, CA

OncologyGrant-only
Compare Sign in to watch

What changed

NIH R44 · $1.1M · Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing

9mo agoGrant renewalSep 24, 2025Source filing (opens the source filing in a new tab)

Momentum

46no change

Momentum 46 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

11,260 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R44 · $1.1M · non-dilutive

    Sep 25, 2025

    SYNTR HEALTH TECHNOLOGIES, LLC · PI ZOBI, AHMED NABIL · NCATS · award ends Aug 31, 2027 · Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing

    NIH RePORTER · NIH RePORTER 11253865 (opens the source filing in a new tab)

  2. Grant

    R43 · $357k · non-dilutive

    Sep 2, 2025

    SYNTR HEALTH TECHNOLOGIES, LLC · PI ZOBI, AHMED NABIL · NCI · award ends Aug 31, 2027 · Accelerating Bioengineering Approaches for Increasing Access to New Solutions Targeting Breast Cancer Reconstructive Surgery

    NIH RePORTER · NIH RePORTER 11253864 (opens the source filing in a new tab)

  3. Grant

    R43 · $407k · non-dilutive

    Aug 15, 2025

    SYNTR HEALTH TECHNOLOGIES, LLC · PI ZOBI, AHMED NABIL · NCATS · award ends Aug 14, 2027 · Rapid and Automated Dissociation of Tumor Tissue for Single Cell Diagnostics

    NIH RePORTER · NIH RePORTER 11070092 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources